Advertisement

Drug Safety

, Volume 19, Issue 1, pp 73–82 | Cite as

Neuroleptic Malignant Syndrome

Recognition, Prevention and Management
  • Varadaraj R. Velamoor
Review Article Drug Safety Concept

Abstract

Neuroleptic malignant syndrome (NMS) is a rare but potentially lethal form of drug-induced hyperthermia characterised by mental status changes, muscle rigidity, hyperthermia and autonomic dysfunction. Increased awareness and early recognition will lead to prompt management. The diagnosis of NMS presents a challenge because several medical conditions generate similar symptoms. The presentation and course of NMS can be quite variable ranging from a stormy and potentially fatal course to a relatively benign and self-limiting course. The most important aspect of treatment is prevention. This includes reducing risk factors (e.g. dehydration, agitation and exhaustion), early recognition of suspected cases and prompt discontinuation of the offending agent. All patients with psychosis should be monitored daily for dehydration and elevated temperature, have vital signs checked and agitation should be watched for. Antipsychotics should be used conservatively with gradual titration of doses. The management of NMS should be based on a hierarchy of symptom severity.

Following an episode of NMS, the patient should be reassessed for further treatment with antipsychotics and rechallenge should not be attempted at least 2 weeks following resolution of symptoms of NMS. The patient and family should be educated about the episode and consent for further medication use obtained after a clear explanation of the risk-benefit analysis.

Keywords

Adis International Limited Dantrolene Neuroleptic Malignant Syndrome Malignant Hyperthermia Serotonin Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Delay J, Pichot P, Lemperiere T, et al. Un neuroleptique majeur non-phenothiazine et non reserpinique, l’haloperidol, dans 1e traitement des psychoses. Ann Med Psychol 1960; 118: 145–52Google Scholar
  2. 2.
    Caroff SN. The neuroleptic malignant syndrome. J Clin Psychiatry 1980; 41: 79–83PubMedGoogle Scholar
  3. 3.
    Delay J, Pichot P, Lemperiere T, et al. L’emploi des butyrophenones en psychiatrie: etude statistique et psychometrique. In: Symposium Internazionale sull’Haloperidol e Triperidol. Milan, Instituto Luso Farmaco d’Italia, 1962; 305–319Google Scholar
  4. 4.
    Keck PE, Pope HG, McElroy SL. Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry 1991; 148: 880–2PubMedGoogle Scholar
  5. 5.
    Gelenberg AJ, Bellinghausen B, Wojcik JD, et al. Aprospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. Am J Psychiatry 1988; 145: 517–8PubMedGoogle Scholar
  6. 6.
    Keck PE, Pope HG, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome: a prospective study. Am J Psychiatry 1987; 144: 1344–6PubMedGoogle Scholar
  7. 7.
    DSM IV. Diagnostic and Statistical manual of metal disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994: 741–2Google Scholar
  8. 8.
    Konikoff F, Kuritzky A, Jerushalmi Y, et al. Neuroleptic malignant syndrome induced by a single injection of haloperidol. BMJ 1984; 289: 1228–9PubMedCrossRefGoogle Scholar
  9. 9.
    Susman VL, Addonizio G. Reinduction of neuroleptic malignant syndrome by lithium. J Clin Psychopharmacol 1987; 7: 339–41PubMedCrossRefGoogle Scholar
  10. 10.
    Goulon M, Rohan-Chabot P, De Elkhaart D, et al. Beneficial effects of dantrolene in the treatment of neuroleptic malignant syndrome: a report of two cases. Neurology 1983; 33: 516–8PubMedGoogle Scholar
  11. 11.
    Weinberg SE, Twerski RS. Neuroleptic malignant syndrome. Anesth Analg 1983; 62: 848–50PubMedCrossRefGoogle Scholar
  12. 12.
    Henderson A, Longdon P. Fulminant metoclopramide-induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene. Aust NZ J Med 1991; 21: 742–3CrossRefGoogle Scholar
  13. 13.
    Lenler-Peterson P, Hansen BD, Hasselstrom L. A rapidly progressing lethal case of neuroleptic malignant syndrome. Intensive Care Med 1990; 16: 267–8CrossRefGoogle Scholar
  14. 14.
    Lavie CJ, Ventura HO, Walker G. Neuroleptic malignant syndrome: three episodes with different drugs. South Med J 1986; 79: 1571–3PubMedCrossRefGoogle Scholar
  15. 15.
    Eiser AR, Neff MS, Slifkin RF. Acute myoglobinuric renal failure. Arch Intern Med 1982; 142: 601–3PubMedCrossRefGoogle Scholar
  16. 16.
    Marsden CD, Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 1980; 10: 55–72PubMedCrossRefGoogle Scholar
  17. 17.
    Henderson VW, Wooten GF. Neuroleptic malignant syndrome; a pathogenetic role for dopamine receptor blockade? Neurology 1981; 31: 132–7PubMedCrossRefGoogle Scholar
  18. 18.
    Behman S. Mutism induced by phenothiazines. Br J Psychiatry 1972; 121: 599–604CrossRefGoogle Scholar
  19. 19.
    Ansseau M, Diricq ST, Grisar TH, et al. Biochemical and neuroendocrine approaches to a malignant syndrome of neuroleptics. Acta Psychiatr Belg 1980; 80: 600–6PubMedGoogle Scholar
  20. 20.
    Tu JB. Psychopharmacogenetic basis of medication-induced movement disorders. Int Clin Psychopharmacol 1997 Jan; 12(1): 1–12PubMedCrossRefGoogle Scholar
  21. 21.
    Deuschal G, Oepen G, Hermle L, et al. Neuroleptic malignant syndrome: observations on altered consciousness. Pharmacopsychiatry 1987; 20: 168–79CrossRefGoogle Scholar
  22. 22.
    Otani K, Horiuchi M, Kondo T, et al. Is the predisposition to neuroleptic malignant syndrome genetically transmitted? Br J Psychiatry 1991; 158: 850–3PubMedCrossRefGoogle Scholar
  23. 23.
    Caroff SN, Mann SC. Neuroleptic malignant syndrome (review). Med Clin North Am 1993; 77: 185–202PubMedGoogle Scholar
  24. 24.
    Caroff SN, Mann SC. Neuroleptic malignant syndrome. Psychopharmacol Bull 1988; 24: 25–9PubMedGoogle Scholar
  25. 25.
    Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 1987; 22: 1004–20PubMedCrossRefGoogle Scholar
  26. 26.
    Velamoor VR, Norman R, Caroff SN, et al. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis 1994; 182: 168–73PubMedCrossRefGoogle Scholar
  27. 27.
    Velamoor VR, Fernando MLD, Williamson P. Incipient neuroleptic malignant syndrome? Br J Psychiatry 1990; 156: 581–4PubMedCrossRefGoogle Scholar
  28. 28.
    Meltzer HY, Cola PA, Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology 1996 Oct; 15(4): 395–405PubMedCrossRefGoogle Scholar
  29. 29.
    Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 1989 Jun; 146(6): 295–8Google Scholar
  30. 30.
    Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 1986; 73: 337–47PubMedCrossRefGoogle Scholar
  31. 31.
    Yamawaki S, Yano E, Uchitomi Y Analysis of 497 cases of neuroleptic malignant syndrome in Japan. Hiroshima J Anesth 1990; 26: 35–44Google Scholar
  32. 32.
    Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993; 77: 185–202PubMedGoogle Scholar
  33. 33.
    Keck PE, Pope HG, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome: a prospective study. Am J Psychiatry 1987; 144: 1344–6PubMedGoogle Scholar
  34. 34.
    White DAC, Robins AH. Catatonia: harbinger of the neuroleptic malignant syndrome. Br J Psychiatry 1991; 158: 419–21PubMedCrossRefGoogle Scholar
  35. 35.
    White DAC. Catatonia and the neuroleptic malignant syndrome: a single entity? Br J Psychiatry 1992; 161: 558–60PubMedCrossRefGoogle Scholar
  36. 36.
    Woodbury MM, Woodbury MA. Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry 1992; 31: 1161–4PubMedCrossRefGoogle Scholar
  37. 37.
    Jauss M, Krack P, Franz M, et al. Imaging of Dopamine receptors with [1–123] iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome. Mov Disord 1996 Nov; 11(6): 726–8PubMedCrossRefGoogle Scholar
  38. 38.
    Velamoor VR, Swamy MB, Parmar MB, et al. Management of suspected neuroleptic malignant syndrome. Can J Psychiatry 1995; 40: 545–8PubMedGoogle Scholar
  39. 39.
    Levenson DF, Simpson GM. Neuroleptic-induced extrapyramidal symptoms with fever: heterogeneity of the neuroleptic malignant syndrome. Arch Gen Psychiatry 1986; 43: 839–48CrossRefGoogle Scholar
  40. 40.
    Sewell D, Jeste DV. Distinguishing neuroleptic malignant syndrome (NMS) from NMS-like acute medical illnesses: a study of 34 cases. J Neuropsychiatry 1992; 4(3): 265–9Google Scholar
  41. 41.
    Raja M, Altavista MC, Cavallari S, et al. Neuroleptic malignant syndrome and catatonia. Eur Arch Psychiatry Clin Neurosci 1994; 243: 299–303PubMedCrossRefGoogle Scholar
  42. 42.
    Bernstein RA. Malignant neuroleptic syndrome: an atypical case. Psychosomatics 1979; 20: 840–6PubMedGoogle Scholar
  43. 43.
    Misiaszek JJ, Potter RL. Atypical neuroleptic malignant syndrome responsive to conservative management. Psychosomatics 1985; 26: 62–6PubMedCrossRefGoogle Scholar
  44. 44.
    Goldman SA. FDA medwatch report - lithium and neuroleptics in combination — the spectrum of neurotoxicity. Psychopharmacol Bull 1996; 32(3): 299–309PubMedGoogle Scholar
  45. 45.
    Martin TG. Serotonin syndrome. Ann Emerg Med 1996; 28(5): 520–6PubMedCrossRefGoogle Scholar
  46. 46.
    Northoff G. Neuroleptic malignant syndrome and catatonia —one entity or two. Biol Psychiatry 1996 Sep; 40(5): 431–2PubMedCrossRefGoogle Scholar
  47. 47.
    Blumer D. Catatonia and the neuroleptics — psychobiologic significance of remote and recent findings. Compr Psychiatry 1997 Jul–Aug; 38(4): 193–201PubMedCrossRefGoogle Scholar
  48. 48.
    Fricchione G, Bush G, Fozdar M, et al. Recognition and treatment of the catatonic syndrome [review]. J Intens Care Med 1997 May–Jun; 12(3): 135–47Google Scholar
  49. 49.
    Castillo E, Rubin RT, Holsboer-Trachsler E. Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. Am J Psychiatry 1989 Mar; 146(3): 324–8PubMedGoogle Scholar
  50. 50.
    Mann SC, Caroff SN, Bleier HR, et al. Lethal catatonia. Am J Psychiatry 1986; 143: 1374–81PubMedGoogle Scholar
  51. 51.
    Kellam AMP. The neuroleptic malignant syndrome, so called: a survey of the world literature. Br J Psychiatry 1987; 150: 752–9PubMedCrossRefGoogle Scholar
  52. 52.
    Topka H, Buchkremer G. Lethal catatonia, malignant neuroleptic malignant syndrome and myositis ossificans. Nervenarzt 1996 May; 67(5): 413–7PubMedGoogle Scholar
  53. 53.
    Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 1997; 17(3); 208–21PubMedCrossRefGoogle Scholar
  54. 54.
    Sporer KA. The serotonin syndrome: implicated drugs, pathophysiology and management. Drug Saf 1995; 13: 94–104PubMedCrossRefGoogle Scholar
  55. 55.
    Caley CF. Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. Ann Pharmacother 1997; 31: 1481–9PubMedGoogle Scholar
  56. 56.
    Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 1989; 50: 18–25PubMedGoogle Scholar
  57. 57.
    Sakkas P, Davis JM, Hua J, et al. Pharmacotherapy of neuroleptic malignant syndrome. Psychiatr Ann 1991; 21: 157–64Google Scholar
  58. 58.
    Sakkas P, Davis JM, Janucak PG, et al. Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull 1991; 27: 381–4PubMedGoogle Scholar
  59. 59.
    Scheftner WA, Shulman RB. Treatment choice in neuroleptic malignant syndrome. Convuls Ther 1992; 8(4): 267–79PubMedGoogle Scholar
  60. 60.
    Davis JM, Janicak PG, Sakkas P, et al. Electroconvulsive therapy in the treatment of the neuroleptic malignant syndrome. Convuls Ther 1991; 7: 111–20PubMedGoogle Scholar
  61. 61.
    Mann SC, Caroff SN, Bleier HR, et al. Electroconvulsive therapy of the lethal catatonia syndrome: case report and review. Convuls Ther 1990; 6: 239–47PubMedGoogle Scholar
  62. 62.
    Lazarus A, Mann SC, Caroff SN. The neuroleptic malignant syndrome and related conditions. Washington, DC: American Psychiatric Press Inc., 1989Google Scholar
  63. 63.
    Jacobson JL, Jacobson AM. Psychiatric secrets. Philadelphia: Hanley and Belfus Inc., 1996: 466Google Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  • Varadaraj R. Velamoor
    • 1
  1. 1.Emergency Psychiatry ProgramLondon Health Science CentreLondonCanada

Personalised recommendations